NMDA Antagonist Combination Therapy for Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, particularly treatment-refractory depression, often fail to provide significant antidepressant effects while also causing side effects such as anxiety, akathisia, and increased suicidality, and combinations of antidepressants do not offer superior efficacy over monotherapy and typically increase side effects.
Innovation Solution
A combination therapy involving an NMDA receptor antagonist, such as D-cycloserine, administered in specific dosages to produce blood levels exceeding 25 micrograms/mL, paired with traditional antidepressants or antipsychotics, to enhance antidepressant effects while minimizing side effects like anxiety and suicidality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressants are used to treat depression, then antidepressant effects are achieved, but side effects such as anxiety, akathisia, and suicidality increase
Solution Approach 1:
An NMDA receptor antagonist is introduced as an intermediary substance that mediates between the antidepressant and the patient's neural system. This intermediary blocks NMDA receptors to produce antidepressant effects while avoiding the harmful side effects of traditional antidepressants, effectively acting as a buffer that achieves therapeutic goals without the detrimental consequences of conventional treatments
Solution Approach 2:
The invention changes the pharmacological parameter from traditional neurotransmitter reuptake inhibition to NMDA receptor antagonism. By shifting the mechanism of action to a different neural pathway (NMDA receptor blockade), the treatment achieves antidepressant efficacy while operating in a different pharmacological space that avoids the side effect profile of conventional antidepressants
2Reliability
If combinations of antidepressants are used to enhance antidepressant effects, then potentially superior efficacy could be achieved, but side effects increase
Solution Approach 1:
The invention merges the NMDA receptor antagonist with traditional antidepressant therapy in a combination regimen. This strategic combination leverages the unique mechanism of NMDA antagonism to enhance overall antidepressant efficacy while the NMDA blocker component helps mitigate the side effects of traditional antidepressants, creating a synergistic effect that improves both efficacy and tolerability
Solution Approach 2:
The treatment approach uses a composite pharmacological strategy combining two different mechanisms of action (NMDA receptor antagonism and traditional antidepressant mechanisms). This composite approach creates a multi-faceted therapeutic effect that addresses depression through multiple pathways while balancing the side effect profile through the complementary actions of the combined agents
Data Source
AI summary
This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.